Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice.

Nature communications - 3 Sept 2021

Novais Emanuel J, Tran Victoria A, Johnston Shira N, Darris Kayla R, Roupas Alex J, Sessions Garrett A, Shapiro Irving M, Diekman Brian O, Risbud Makarand V

Abstract excerpt

Intervertebral disc degeneration is highly prevalent within the elderly population and is a leading cause of chronic back pain and disability. Due to the link between disc degeneration and senescence, we explored the ability of the Dasatinib and Quercetin drug combination (D + Q) to prevent an age-dependent progression of disc degeneration in mice. We treated C57BL/6 mice beginning at 6, 14, and 18 months of age,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aggrecans
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Extracellular Matrix

Share to Fibrosis

Share to Inflammation

Share to Intervertebral Disc Degeneration

Share to Quercetin

Source

Open in PubMed Open full text

Identifiers

PMID: 34480023
DOI: 10.1038/s41467-021-25453-2
PMCID: PMC8417260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice.PMID 34480023Read ↗

Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc DegenerationSemantic proximity Read ↗

Plant-Derived Senotherapeutics for the Prevention and Treatment of Intervertebral Disc Degeneration and AgingSemantic proximity Read ↗

Senotherapeutic drugs for human intervertebral disc degeneration and low back painSemantic proximity Read ↗

Targeting Cellular Senescence: Pathophysiology in Multisystem Age-Related DiseasesSemantic proximity Read ↗

Aging, cell senescence, the pathogenesis and targeted therapies of intervertebral disc degenerationSemantic proximity Read ↗

Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by promoting the release of pro-anabolic mediatorsSemantic proximity Read ↗

Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by the release of pro-anabolic mediators.Semantic proximity Read ↗

A Standardized In Vitro Platform for Senolytic Drug Discovery in Human Musculoskeletal CellsSemantic proximity Read ↗

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugsSemantic proximity Read ↗

Oxidative stress-induced circKIF18A downregulation impairs MCM7-mediated anti-senescence in intervertebral disc degenerationSemantic proximity Read ↗

Cellular senescence and other age-related mechanisms in skeletal diseasesSemantic proximity Read ↗

Senolytic Treatment for Low Back PainSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.